Page last updated: 2024-11-12
depudecin
Description
depudecin: structure given in first source; isolated from the fungus Alternaria brassicicola [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
depudecin : A polyketide obtained from the fungus Alternaria brassicicola and having a highly unusual structure of an 11-carbon chain containing two epoxides and six stereogenic centres. It is an inhibitor of histone deacetylase (HDAC) both in vivo and in vitro and also exhibits anti-angiogenic activity. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 16219259 |
| CHEBI ID | 64143 |
| SCHEMBL ID | 1248372 |
| MeSH ID | M0195825 |
Synonyms (18)
| Synonym |
|---|
| SMP2_000165 |
| HDINHIB_000060 |
| depudecin |
| (-)-depudecin, >95% (hplc), from microbial |
| oxiranemethanol, alpha-ethenyl-3-(2-(3-(1-hydroxyethyl)oxiranyl)ethenyl)-, (2s-(2r*(e(2r*(s*),3r*)),3r*(s*)))- |
| 139508-73-9 |
| (-)-depudecin |
| (1r)-1-{(2s,3s)-3-[(e)-2-{(2s,3s)-3-[(1r)-1-hydroxyethyl]oxiran-2-yl}ethenyl]oxiran-2-yl}prop-2-en-1-ol |
| (1s,3e,6s)-1,2:5,6-dianhydro-3,4-dideoxy-1-[(1r)-1-hydroxyethyl]-6-[(1r)-1-hydroxyprop-2-en-1-yl]-d-threo-hex-3-enitol |
| CHEBI:64143 |
| 4,5:8,9-dianhydro-1,2,6,7,11-pentadeoxy-d-threo-d-ido-undeca-1,6-dienitol |
| AKOS025294472 |
| SCHEMBL1248372 |
| J-007287 |
| Q27133063 |
| DTXSID201017129 |
| CS-0113179 |
| HY-135476 |
Research Excerpts
Overview
Depudecin is a fungal metabolite that reverts the rounded phenotype of NIH3T3 fibroblasts transformed with v-ras and v-src oncogenes.
| Excerpt | Reference | Relevance |
|---|
| "(-)-Depudecin is a fungal metabolite that reverts the rounded phenotype of NIH3T3 fibroblasts transformed with v-ras and v-src oncogenes to the flat phenotype of the nontransformed parental cells. " | ( Synthesis and cellular characterization of the detransformation agent, (-)-depudecin.
Kwon, HJ; Sawamura, M; Schreiber, SL; Shimada, J, 1995) | 1.08 |
| "Depudecin is a fungal metabolite that reverts the rounded phenotype of NIH 3T3 fibroblasts transformed with v-ras and v-src oncogenes to the flattened phenotype of the nontransformed parental cells. " | ( Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase.
Hassig, CA; Kwon, HJ; Owa, T; Schreiber, SL; Shimada, J, 1998) | 3.19 |
Roles (2)
| Role | Description |
|---|
| EC 3.5.1.98 (histone deacetylase) inhibitor | An EC 3.5.1.* (non-peptide linear amide C-N hydrolase) inhibitor that interferes with the function of histone deacetylase (EC 3.5.1.98). |
| fungal metabolite | Any eukaryotic metabolite produced during a metabolic reaction in fungi, the kingdom that includes microorganisms such as the yeasts and moulds. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (1)
| Class | Description |
|---|
| polyketide | Natural and synthetic compounds containing alternating carbonyl and methylene groups ('beta-polyketones'), biogenetically derived from repeated condensation of acetyl coenzyme A (via malonyl coenzyme A), and usually the compounds derived from them by further condensations, etc. Considered by many to be synonymous with the less frequently used terms acetogenins and ketides. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (12)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (50.00) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 2 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 21.03
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 21.03 (24.57) | | Research Supply Index | 2.64 (2.92) | | Research Growth Index | 4.37 (4.65) | | Search Engine Demand Index | 18.60 (26.88) | | Search Engine Supply Index | 2.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 13 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |